Skylar Jeremias

Three-year trial data show baricitinib sustains and deepens hair, eyebrow, and eyelash regrowth in severe alopecia areata, with stable long-term safety.

During a White House briefing, Mehmet Oz, MD, discussed the expansion of Trump Rx and crackdowns on duplicate ACA enrollment and fraudulent hospice programs.

Everyday skincare may expose you to microplastics and plastic-linked chemicals tied to skin disease and hormone disruption; dermatologists urge safer products and packaging.

The update makes biologics first-line treatment, adds comorbidity management guidance, and aligns practice with evolving European guidelines for psoriasis.

Systematic review finds SGLT2 inhibitors and newer CKD drugs boost QALYs and often save costs by delaying dialysis and transplant.

New US chronic hand eczema guidance closes diagnostic gaps and spotlights emerging therapies like delgocitinib to cut itch, pain, and work disruption.

Cancer survivors face lasting skin, hair, and nail reactions; dermatology follow-up and treatments can restore appearance, improve quality of life, and monitor risks.

Meta-analysis finds alopecia areata links to lower melanoma odds and no added skin cancer risk despite ultraviolet-exposed scalp, informing Janus kinase inhibitor safety.

Study finds endometriosis severity plateaus after 30, but surgery risk and complexity climb in older women as fibrosis and adhesions build.

Phenotype-based care improves childhood obesity diagnosis and treatment, including obesity types, hypothalamic obesity, drugs, and surgery.

The scoping review shows menopause and multiple sclerosis (MS) shift from fewer relapses to higher symptom burden, highlighting care gaps for older women with MS.

Phase 3 THRIVE-AA2 data show deuruxolitinib in alopecia areata boosts hair regrowth and satisfaction in severe AA, with manageable safety, vs placebo.

Data from the STEPIn trial shows early intervention for plaque psoriasis with secukinumab delivers durable disease control, with some staying clear up to a year post treatment.

Psoriasis and macrophage research spotlights M1/M2 imbalance, interleukin therapies, and single-cell insights pointing to new precision targets.

New evidence links alopecia areata and atopic dermatitis overlap, revealing eczema-like immune signatures and dual-use JAK/OX40 therapies to watch.

Photodynamic therapy expands from actinic keratosis to acne, infections, and rejuvenation—while experts urge clearer, mechanism-based guidelines.

Global pediatric HIV data show dolutegravir links to early modest weight gain that plateaus by year 2, easing concerns and highlighting regional nutrition gaps.

A global cohort has tracked pediatric HIV growth after dolutegravir, showing early catch-up weight gain, then stable BMI without long-term obesity risk.

A federal court blocked RFK Jr's vaccine agenda, freezing the ACIP shakeup and safeguarding child vaccine access as the legal fight over vaccines intensifies.

Study links PFAS and forever chemicals in children and teens to lower bone density in adolescents—especially girls—highlighting critical exposure windows.

Peter Staley at CROI 2026 on defending 45 years of HIV progress: how clinicians, payers, and advocates can resist—quietly or publicly—and why it matters.

Elona Toska, MSc, DPhil, explores drivers of HIV in pregnant women and young mothers: biology, relationships, and postpartum treatment drop-off.

From innovative therapies to global care strategies, HIV experts at CROI 2026 share the breakthroughs and lessons they hope every viewer, near or far, takes home.

Wildfire smoke from the Canadian wildfires in 2023 was linked to a higher incidence of severe strokes and increased hemorrhagic risk, according to new study findings.

Phase 3 data show povorcitinib delivers rapid lesion clearance in HS, improves quality of life outcomes, and offers favorable safety through 24 weeks.

Elona Toska, MSc, DPhil, explores drivers of HIV in pregnant women and young mothers: biology, relationships, and postpartum treatment drop-off.

Sweeping federal funding cuts and stalled prevention efforts are unraveling hard-won gains in HIV research and access, warns Peter Staley.

Todd Brown, MD, PhD, explains key considerations for using GLP‑1 drugs in patients with HIV, including titration tips, surgery precautions, and bone/muscle monitoring.

At CROI 2026, experts warned that missing HBV screening risks reactivation during HIV therapy switches.